London Stock Exchange welcomes Diaceutics Plc to AIM

London Stock Exchange welcomes Diaceutics Plc to AIM

London Stock Exchange today welcomes Diaceutics plc (‘Diaceutics’ or the ‘Company’), a data analytics and implementation services company focussed on the global pharmaceutical industry, to celebrate the listing of the Company's public shares onto AIM, under the ticker 'DXRX'.

Diaceutics has established a suite of data-driven products and implementation services powered by the data held in its proprietary database. Its products and services are focused on optimising its clients’ strategies for the development and launch of precision medicines and specifically, the diagnostic testing required to guide selection of such medicines. The Company currently provides services to 20 of the 30 largest global pharmaceutical companies.

Since its inception in 2005, Diaceutics has focused on the diagnostic testing market, collating large amounts of laboratory, patient (on an anonymised and aggregated basis), claims and payor data which it uses to deliver diagnostic testing strategies to its clients. The Group has amassed a set of data from over 2,500 laboratories including 3.5m longitudinal patient records, insurance claims data for 50m patients and 58m testing event data points from 35 countries. As part of this data collection, it has accumulated a proprietary database of laboratory capabilities across the industry.

The Company raised £17m by way of a placing at a price of 76p per share through its nominated adviser and broker, Cenkos Securities plc; as well as placing an additional £3.75m on behalf of existing shareholders. The Company listed on AIM at 8am on the 21 March 2019 and shares trade under the AIM symbol 'DXRX'. Diaceutics is expected to have a market capitalisation on admission of around £53m.

Peter Keeling, CEO, Diaceutics, said: 
"Diaceutics was founded out of a desire to get more patients access to improved healthcare. We are giving patients a higher likelihood of getting better by supporting access to the right test to determine the right treatment at the right time. Our AIM IPO will help us in our mission to continue this great work."

To find out more about Diaceutics visit: